cas 1778-09-2|| where to buy 1-(4-(Methylthio)phenyl)ethanone

Product Name:1-(4-(Methylthio)phenyl)ethanone

IUPAC Name:1-[4-(methylsulfanyl)phenyl]ethan-1-one

Packing Unit	Available Stock	Price($)
CM250395-50g	in stock	ŽĨ
CM250395-100g	in stock	ƩŁĨ
CM250395-500g	in stock	řƩŽ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1778-09-2 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1778-09-2; Molecular Formula:C9H10OS; Melting Point:-; Smiles Code:CC(C1=CC=C(SC)C=C1)=O; Density:

: Catalog Number:CM250395; Molecular Weight:166.24; Boiling Point:135°C at 1 mmHg; MDL No:MFCD00039835; Storage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Elafibranor; Nov 13, 2023, ELATIVE® Phase III trial confirms potential for investigational elafibranor as a first-in-class, dual PPAR α,δ agonist for patients with Primary Biliary Cholangitis.
Elafibranor is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta (α,δ) agonist, currently under investigation as a treatment for patients with PBC, a rare liver disease. Concurrent α,δ activation targets inflammation, cholestasis and fibrosis in PBC.